The headline safety figures — and what they mean for hip patients

For patients considering a ChondroFiller® injection at a hip clinic in Lincolnshire or elsewhere in the UK, the most pressing question is straightforward: how safe is it? The most authoritative answer currently available comes from the manufacturer's Version 09 Clinical Evaluation Report (CER), dated April 2025, which synthesises accumulated post-market surveillance across more than 19,000 treated cases globally.

Across that dataset, the reported complication rate sits at approximately 0% — the lowest figure among all cartilage repair modalities reviewed in the CER's comparative analysis. The reoperation rate is 3–8%, which compares favourably with microfracture (up to 41%) and ACI/MACI (up to 37%); ACI/MACI alone carries a complication rate of up to 17%.

Two caveats deserve equal prominence. First, the 19,000 cases span multiple joints — knee, hip, ankle, and small joints — and no published hip-only safety series has isolated the hip contribution. The figure is cited with moderate confidence, not as a precise hip-specific count. Second, this evidence derives from the manufacturer's own post-market surveillance programme, not an independent randomised controlled trial. That distinction matters: the data are real-world and substantial, but they have not yet been replicated in an independent large-scale RCT specifically for the hip.

For patients weighing their options, these figures provide a reasonable starting point for a conversation with a clinician, not a guarantee of any individual outcome.

Why the injection route itself lowers procedural risk

The delivery method itself accounts for a substantial share of ChondroFiller®'s favourable risk profile. Placing the scaffold via an ultrasound-guided intra-articular injection into the hip joint — performed as an outpatient appointment, under local anaesthesia, without surgical incision — removes the procedural risk layer that accompanies open or arthroscopic alternatives. There is no theatre admission, no general anaesthetic, no wound to close, and no risk of haematoma or wound-site infection. Each of those surgical steps carries its own documented complication exposure; removing them collectively narrows the overall risk profile.

The injectable route also sidesteps the need for aggressive joint preparation. ChondroFiller® is placed into the hip's natural fluid environment, adhering directly over the focal cartilage defect. No surgically dried joint bed is required, and no debridement of surrounding tissue precedes it — a contrast to surgical cartilage procedures where joint preparation itself introduces procedural risk.

Infection risk at the procedural level is addressed by including intravenous antibiotic cover as standard within the injection protocol. Combined with real-time ultrasound guidance — a well-established standard for hip joint injection delivery, supported by a broad intra-articular hip injection literature — the result is an image-guided placement pathway in which identifiable surgical risks have, structurally, been designed out rather than simply managed after the fact.

Hip-specific outcomes: Harris Hip Score and structural repair data

Published hip data give the most direct read on what ChondroFiller® achieves once placed in a damaged joint. In patients with focal hip cartilage defects and femoroacetabular impingement (FAI), Harris Hip Score (HHS) improvements of approximately +33 points have been reported — a margin that clears the threshold for clinical meaningfulness and translates practically into reduced pain and better daily function.

Structural repair quality is tracked via MOCART MRI scoring. European studies consistently record scores of 81.6 to 84.3, meaning more than 80% of the original defect volume is filled with organised repair tissue that integrates with the surrounding native cartilage. That process does not happen instantly: MOCART scores progress from 65.3 at four weeks to 81.6 at one year, reflecting the scaffold's role in acellular matrix-induced chondrogenesis — recruiting the patient's own progenitor cells from the synovium and subchondral bone rather than delivering cartilage directly.

Longer-term data from the Jerosch et al. prospective post-market clinical follow-up (PMCF) study record a mean IKDC improvement of 32.4 points at three years, exceeding the minimum clinically important difference of 16.7 points. Although IKDC is a knee-validated instrument used here as a parallel functional benchmark, the direction and magnitude align with the hip-specific HHS findings. At five years, HHS, IKDC, and MOCART scores remain stable, and no late immunogenic or inflammatory adverse events attributable to the murine-derived Type I collagen scaffold have emerged in the available literature.

Patient selection and why it shapes the safety profile

The near-zero complication figure reported in the CER does not apply to every hip patient — it reflects a carefully defined cohort, and understanding that distinction is essential when reading the safety data.

ChondroFiller® is indicated for focal Grade III or IV articular cartilage defects up to 6 cm² with intact, healthy surrounding cartilage borders. Patients with diffuse, end-stage Kellgren-Lawrence Grade IV osteoarthritis of the hip do not fall within that indication; the safety profile generated across 19,000 cases does not transfer to that all-comers population, and for them a different pathway — including hip preservation surgery or joint replacement — is typically more appropriate.

The acellular design removes one category of risk outright: because ChondroFiller® contains no donor cells and requires no harvest site, there is no immune-mediated rejection risk and no secondary wound. Its murine-derived Type I collagen origin does, however, mean that routine animal-protein sensitivity screening is applied before treatment — a standard precaution, not a barrier for the majority of suitable patients.

Patients with femoroacetabular impingement (FAI) may be candidates where the underlying structural problem has already been addressed, or where injection rather than further structural correction is the agreed treatment aim.

In practice, thorough pre-injection assessment — confirming a focal, contained defect with appropriate hip mechanics — functions as a risk-reduction step in its own right, upstream of the procedure itself.

How ChondroFiller's safety compares to surgical cartilage repair options

The figures cited in the opening section — approximately 0% complications and 3–8% reoperation for ChondroFiller®, against up to 17% complications and 37% reoperation for ACI/MACI, and up to 41% reoperation for microfracture — reflect more than a product-to-product difference. They reflect fundamentally different clinical pathways, each carrying its own risk architecture.

Surgical cartilage repair procedures for the hip involve general or regional anaesthesia, theatre admission, and active joint preparation — all of which introduce risk categories that an outpatient injection does not encounter. ACI and MACI procedures additionally require a harvest stage: cartilage biopsy taken from a low-load area of the joint, followed by laboratory cell culture or membrane preparation before reimplantation. That two-stage process creates a secondary wound site and the possibility of harvest-site morbidity, neither of which applies to an acellular injectable scaffold with no donor-cell component.

ChondroFiller® also avoids the joint-bed debridement step that conventional surgical repair requires to create a clean surface for graft or membrane fixation. Being delivered into a fluid joint environment under ultrasound guidance, the scaffold is placed additively — the articular surface is not surgically prepared as part of the procedure.

For patients weighing these options, it is worth noting that surgical cartilage procedures and ChondroFiller® injection serve overlapping but not identical indications. Both target focal, contained defects rather than diffuse joint degeneration, but the surgical route may be selected where defect size, depth, or mechanical alignment considerations place the case outside the injection pathway's scope. A consultant assessment determines which route is appropriate for an individual hip.

The broader safety context for hip injection is supported by a 2023 retrospective evaluation of 682 hips receiving intra-articular injections, which found no increased risk of periprosthetic joint infection relative to subsequent arthroplasty when an interval of six to seven months was maintained — a finding that positions injection as a legitimate earlier-pathway option rather than one that compromises later surgical options.

Evidence gaps patients should know about

The accumulated evidence — approximately 0% complications across 19,000+ cases, Harris Hip Score gains of +33 points in hip applications, and MOCART scores above 80 at one year, sustained at five years — presents a coherent safety picture for a carefully selected patient group. For someone with a confirmed focal Grade III/IV hip cartilage defect who fits the indication, that picture is genuinely informative.

Two things deserve direct acknowledgement before any consultation. All primary data originates from the manufacturer's post-market surveillance programme (CER, Version 09, April 2025) rather than an independent randomised controlled trial, and the 19,000-case dataset spans multiple joints — no hip-specific safety series yet isolates the hip contribution. The CER is a substantial regulatory synthesis; the limitation lies in its character, not its size.

The most useful consultation question is therefore not whether ChondroFiller® is safe in general — for the right patient, the data consistently support it — but whether a specific hip and defect fall within the studied population. Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral, with clinics in Sleaford and Grantham, where imaging and clinical assessment can answer that question directly. Understanding the evidence's scope is what makes that conversation productive.